Free shipping on all orders over $ 500

MGCD265

Cat. No. M1922

All AbMole products are for research use only, cannot be used for human consumption.

MGCD265 Structure
Size Price Availability Quantity
2mg USD 70  USD70 In stock
5mg USD 100  USD100 In stock
10mg USD 160  USD160 In stock
25mg USD 320  USD320 In stock
50mg USD 540  USD540 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

MGCD265 is an orally bioavailable, small molecule tyrosine kinase inhibitor of Met, VEGFR1, VEGFR2, VEGFR3, Ron, and Tie2 with IC50 of 1 nM, 3 nM, 3 nM, 4 nM, 2 nM and 7 nM, respectively. Dysregulation of Met signaling has been implicated in the initiation, progression and metastasis of human cancers. Met is overexpressed in non-small-cell lung cancer and its lack of staining in normal lung tissue makes it an attractive target. Inhibition of these RTKs and their downstream signaling pathways may result in the inhibition of tumor angiogenesis and tumor cell proliferation in tumors overexpressing these RTKs. MGCD-265 has demonstrated a favorable safety profile and can be combined safely with other cancer therapeutics such as docetaxel and erlotinib. In preclinical studies, MGCD265 demonstrated nanomolar potency in enzyme and cellular assays and up to 100% of tumor growth inhibition in a broad range of xenograft models. Daily oral administration of MGCD265 was found to be well tolerated at doses of 24, 48 and 96 mg/m2.

Chemical Information
Molecular Weight 517.6
Formula C26H20FN5O2S2
CAS Number 875337-44-3
Solubility (25°C) DMSO 100 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Belalcazar A, et al. Expert Rev Anticancer Ther. Targeting the Met pathway in lung cancer.

Related c-Met Products
Zurletrectinib

Zurletrectinib (ICP-723) is a potent tyrosine kinase inhibitor. Zurletrectinib serves as an antineoplastic agent. Zurletrectinib can used for research of TRK-mediated related diseases.

ABN401 

ABN401 is a highly potent and selective ATP-competitive c-MET inhibitor with an IC50 value of 10 nM.

(Z)-Semaxanib

(Z)-Semaxanib is a potent tyrosine kinase inhibitor.

MET kinase-IN-2 

MET kinase-IN-2 is a potent, selective, orally bioavailable MET kinase inhibitor with an IC50 of 7.4 nM.

BMS-817378

BMS-817378 is a potent and selective inhibitor of MET with IC50 of 1.7 nM.

  Catalog
Abmole Inhibitor Catalog




Keywords: MGCD265 supplier, c-Met, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.